Performance Evaluation of the Quantamatrix QMAC-dRAST System for Rapid Antibiotic Susceptibility Testing Directly from Blood Cultures
1
Institute of Microbiology, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland
2
Unilabs, 1296 Coppet, Switzerland
3
ADMED Microbiology, 2300 La Chaux-de-Fonds, Switzerland
*
Author to whom correspondence should be addressed.
Microorganisms 2022, 10(6), 1212; https://doi.org/10.3390/microorganisms10061212
Submission received: 3 June 2022
/
Revised: 10 June 2022
/
Accepted: 12 June 2022
/
Published: 14 June 2022
Abstract
:Objectives: Rapid antibiotic susceptibility testing (AST) for positive blood cultures can improve patient clinical outcomes if the time to an effective antimicrobial therapy is shortened. In this study, we tested the Quantamatrix dRAST system (QMAC-dRAST), a rapid AST system based on time-lapse microscopic imagery of bacterial colony formation in agarose. Methods: Evaluation of the QMAC-dRAST was performed from 250 monobacterial blood cultures including 130 Enterobacterales, 20 non-fermentative Gram-negative bacteria, 69 staphylococci and 31 enterococci. Blood cultures were recovered from anonymous patients or from spiking experiments to enrich our study with bacterial species and resistant strains. Categorical agreement (CA), minor errors (me), major errors (ME) and very major errors (VME) were calculated in comparison to the results obtained from the BD Phoenix™ M50. Discrepancies between the Phoenix™ M50 and QMAC-dRAST results were investigated using the gradient strip method. The repeatability and reproducibility performance of the QMAC-dRAST was assessed for 16 strains, each strain being tested five times from a spiked blood culture. Results: The overall CAs for Enterobacterales, non-fermentative Gram-negative bacteria, staphylococci and enterococci were 95.1%, 91.2%, 93.4% and 94.5%, respectively. The VME percentage was below 4% for all the groups except for staphylococci, which showed a VME rate of 7%. The median time to result was 6.7 h (range: 4.7–7.9). Repeatability and reproducibility assays showed a high reliability of AST results with best and worst ratios of 98.8% and 99.6% and 95.0% and 98.3%, respectively. Conclusions: The QMAC-dRAST is a fast and reliable system to determine AST directly from monobacterial blood cultures with a major TAT reduction compared to conventional AST testing.
1. Introduction
Over 1,200,000 persons develop bloodstream infections each year in Europe with a mortality rate of 21.6–37.8 per 100,000 person-years [1]. Rapid administration of an effective targeted antibiotherapy improves patient clinical outcomes by decreasing mortality and morbidity [1,2,3]. It is also associated with a shorter stay in hospital, thereby reducing the costs of care [4]. Conventional AST procedures usually consist of subculturing positive blood samples overnight to measure AST the following day directly from isolated bacterial colonies. Under these conditions antibiotic susceptibility profiles are typically delivered 24 to 72 h after blood culture positivity [5,6].
Reducing the time to when the AST results of a bloodstream infection are available is challenging, and different techniques and automates have been developed for this purpose [7,8]. Innovative technologies are currently being widely assessed in routine laboratories such as the detection of antimicrobial resistance by single-cell morphology analysis or nano-mechanical sensors [9,10]. However, most of these methods are currently not suitable for routine AST and new technologies are still needed for faster diagnosis of bloodstream infection.
The Quantamatrix dRAST (QMAC-dRAST) device is a rapid and automated system, which allows AST directly from blood. It is composed of a microfluidic agarose channel (MAC) system that immobilizes bacteria in agarose-containing microfluidic chambers. Bacterial growth under different antibiotic culture conditions is tracked by time-lapse imaging [11]. In this study, accuracy and repeatability of the QMAC-dRAST were evaluated in comparison to the Becton Dickinson (BD) Phoenix™ M50 device, a well-validated automated AST system [12,13,14,15,16].
2. Methods
Samples. Evaluation of the QMAC-dRAST v2.5 in comparison to the Phoenix™ M50 (BD, Franklin Lakes, NJ, USA) was conducted from 250 blood cultures in the bacteriology laboratory of the Lausanne University hospital, Switzerland. Monobacterial blood cultures were recovered from anonymous patients or from spiking experiments. All blood culture samples were incubated on the BD BACTEC™ FX system (BD, USA). Gram staining was performed to determine whether a Gram-positive or a Gram-negative antibiotic panel was required and to exclude mixed blood cultures.
Spiking experiments. All the bacteria were thawed and subcultured twice onto Columbia agar plates at 37 °C in 5% CO2 atmosphere. Bacterial identification was confirmed by MALDI-TOF on a Microflex LT instrument (Bruker Daltonics). Bacterial suspensions diluted in 0.85% sodium chloride buffer were adjusted to defined bacterial concentrations: 1.5 × 101 bacteria/mL for Pseudomonas aeruginosa, staphylococci and enterococci, and 0.3 × 101 bacteria/mL for Enterobacterales. These concentrations were chosen to reflect the physiological conditions of bloodstream infections. BD BACTEC™ Plus Aerobic or Anaerobic media were inoculated with 5 mL of these suspensions and incubated in the BD BACTEC™ FX system until flagged positive. The median time of positivity for spiked blood cultures was 11.5, 14.1, 15.5 and 11.5 h for Enterobacterales, non-fermentative Gram-negative bacilli (GNB), Staphylococcus and Enterococcus bacteria, respectively.
Antibiotic susceptibility testing. Positive blood cultures were collected and bacterial pellets were prepared with the Rapid BACpro® II kit (Nittobo Medical Co., Ltd., Tokyo, Japan) [17] for bacterial identification by MALDI-TOF on a Microflex LT instrument (Bruker Daltonics) and for Gram staining. Gram staining was performed from both native positive blood culture and from bacterial pellets to characterize Gram-positive and Gram-negative bacteria when no MALDI-TOF identification was obtained and to exclude mixed blood cultures. A 500 µL blood sample was introduced in the QMAC-dRAST system using either a Gram-positive or a Gram-negative panel. For the Phoenix™ M50 (BD) standard methods, blood samples were subcultured for 18 h to 24 h at 37 °C in 5% CO2 on Columbia agar plates (BD). Bacterial colonies were identified by conventional MALDI-TOF and 25 µL of a 0.5 MacFarland bacterial suspension was prepared from isolated colonies to perform a NMIC-502 g-negative panel or in a PMIC-96 g-positive panel. Tetracycline, piperacillin and erythromycin were not included for the comparison between the QMAC-dRAST and the Phoenix™ M50 since these antibiotics are not recommended as first-line therapy for bloodstream infections. Rifampicin was also excluded from our evaluation as the minimal MIC calculated by the Phoenix™ M50 did not discriminate between susceptible (S) and susceptible at increased exposure (I) interpretations according to the 2019 EUCAST guidelines. Colistin was not analyzed since the only recommended method is broth microdilution.
Characterization of resistant phenotypes. Resistant phenotypes were characterized according to AST results combined with standard methods of detection. For extended spectrum β-lactamases (ESBL), synergy tests between diffusion disks of clavulanate and cephalosporins were used as well as PM-PML gradient strips (bioMérieux, Marcy-l’Étoile, France), NG-Test® CTX-M Multi (NG Biotech, Guipry, France) or BETA-LACTA™ chromogenic hydrolysis-based assays [18]. Carbapenemase producers were detected with NG-Test® CARBA 5 (NG Biotech) or Carba NP tests [19]. Twelve carbapenemases were tested including seven OXA-48, one OXA-23, one IMP, one KPC-2 and two uncharacterized carbapenemases. Fifty-one Enterobacterales producing an AmpC β-lactamases (acquired or chromosomal) were tested with CN-CNI gradient strips (Biomerieux). Three natural and eight acquired vancomycin-resistant enterococci (VRE) were included in the study, the latter being identified using selective media (Oxoid) and the Xpert vanA/vanB molecular assays (Cepheid). Twenty-nine methicillin-resistant staphylococci were characterized with cefoxitin screens and Xpert MRSA/SA BC assays (Cepheid, Sunnyvale, CA, USA).
Repeatability and reproducibility. Analysis of AST measurement repeatability and reproducibility was performed on 8 GNB and 8 Gram-positive cocci (GPC), each strain being tested 5 times from a single blood culture for repeatability and from 5 different blood cultures for reproducibility. The mode values correspond to the most frequently occurring minimal inhibitory concentration (MIC) result for each antibiotic tested by the QMAC-dRAST. The best and worst cases were calculated, the best case calculation assuming the off-scale result is within one well from the mode and the worst case calculation assuming the off-scale result is greater than one well from the mode [20].
Evaluation of the QMAC-dRAST performance. Categorical agreement (CA), minor errors (me), major errors (ME) and very major errors (VME) were defined according to the US Food and Drug Administration (FDA) [20]. CA is defined as agreement of test results interpreted within the same susceptibility category (S/I/resistant (R)). AST discordance results were classified as VME (reported S with the QMAC-dRAST when R with the Phoenix™ M50), ME (reported R when S with the Phoenix™ M50) and me (reported I when S or R on the Phoenix™ M50 or reported R or S when I on the Phoenix™ M50). The percentage of ME and VME were evaluated with the total number of strains susceptible or resistant to each antibiotic, respectively. Discrepancies between QMAC-dRAST and Phoenix™ M50 results (ME with a difference in MIC values > 2 two-fold dilutions and all the VME) were investigated using MIC gradient strips on Mueller-Hinton agar (Oxoid) following EUCAST guidelines. Differences in results for clindamycin-inducible resistance were resolved via a D-test (Oxoid) [21]. For oxacillin discrepancies, a cefoxitin disk (Oxoid) was used. Isolates were classified as S/I/R following the 2019 EUCAST breakpoints. Quality controls for the QMAC-dRAST and the BD Phoenix™ M50 were performed according to the manufacturer’s recommendations using the indicated ATCC isolates.
3. Results
3.1. QMAC-dRAST Performance
To assess the QMAC-dRAST performance, 250 bacterial strains were evaluated from 56 blood cultures from anonymous patients and 194 spiked blood cultures. Spiked blood cultures were included to enrich our study in bacterial species and in antimicrobial resistance mechanisms (Table 1). Overall, 130 Enterobacterales, 20 non-fermentative Gram-negative bacilli (GNB), 69 staphylococci and 31 enterococci were evaluated (Table 1). The antibiotics tested for each bacterial group are shown in Supplementary Table S1. Essential agreement was not calculated as most of the reference and QMAC-dRAST MIC results fell in the less than or greater than categories, which are not evaluable according to the FDA guidelines (Supplementary Tables S2–S25) [20].
The rates of CA, VME, ME and me were 95.1%, 1.1%, 1.4% and 3.6% for Enterobacterales, 91.2%, 4%, 4.4% and 4.7% for non-fermentative GNB, 93.4%, 7%, 6.1% and 0.3% for staphylococci and 94.5%, 2.8%, 4.1% and 1.7% for enterococci, respectively (Supplementary Table S26).
AST results were then analyzed per antimicrobial agents (Table 2). For Enterobacterales, ME and VME rates were below 6% for all antibiotics with 88.2% (15/17) of the ME and 75% (3/4) of the VME observed with β-lactams. For non-fermentative GNB, a VME rate of 25% (2/8) was obtained for levofloxacin with Pseudomonas aeruginosa and ME rates of 22.2% (2/9), 20% (2/10) and 16.7% (1/6) were observed with cefepime, piperacillin–tazobactam and trimethoprim–sulfamethoxazole, respectively (Table 2). For enterococcal strains, a VME was observed with linezolid (1/1) and ME rates of 11.1% (2/18) with levofloxacin, 8% (2/25) with ampicillin, 3.7% (1/27) with gentamicin and 4.8% (1/21) with vancomycin were observed (Table 2). More errors were obtained for Staphylococcus species with 23 errors occurring with oxacillin (ME of 50% (16/32) and VME of 18.9% (7/37)) (Table 2). However, the cefoxitin screen performed for Staphylococcus aureus and Staphylococcus lugdunensis was correct for all isolates. A high ME rate of 17% (8/48) was also observed with levofloxacin.
The QMAC-dRAST performs an ESBL screen only for Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae and Proteus mirabilis. For these species, 100% (21/21) of ESBL screens were positive and 5.8% (3/52) of false positives were detected among non-ESBL producing isolates. The false positive ESBL screens occurred with a K. oxytoca K1 strain, a K. pneumoniae hyperproducing SHV-1 and a wild type P. mirabilis. For the 12 carbapenemase-producing GNB, resistance to β-lactams was well detected and no VME was reported in comparison to the Phoenix™ M50 AST results. For the 29 tested methicillin-resistant Staphylococcal isolates, VME errors were observed with oxacillin for Staphylococcus aureus but the cefoxitin screen was always positive. All the methicillin-resistant coagulase-negative Staphylococcus (ConS) were correctly identified with MIC values of oxacillin interpreted as resistant by the QMAC-dRAST.
3.2. Time to AST Results
Median time to the AST result for the bacterial classes and antimicrobial agents is shown in Figure 1. The overall median turnaround time (TAT) was 6.7 h (range: 4.7–7.9). The median TAT was 6.7 h for Enterobacterales (range: 4.7–7.9), 6.7 h for non-fermentative GNB (range: 4.9–7.3), 6.7 h for staphylococci (range: 6.6–7.8) and 7.2 h for enterococci (range: 6.6–7.9) (Figure 1A). For GPC, results were more dispersed than for GNB. No significant difference in median TAT was observed between the different antibiotics tested for each bacterial group (Figure 1B–E).
3.3. Repeatability and Reproducibility
The results from the repeatability and reproducibility experiments are shown in Table 3 and Table 4. Sixteen strains were tested five times on the QMAC-dRAST. Overall, repeatability provided robust results with best and worst ratios of 98.8% and 99.6%, respectively, and mostly non-significant changes in MIC value interpretation. For GNB, 5.6% of MIC variations were within ±1 two-fold dilutions of the mode value and 0.3% within ±2 two-fold dilutions. For GPC, 7.7%, 1.4% and 0.9% of MIC variations were in a range of ±1, 2 and >2 two-fold dilutions, respectively, compared to the mode values. Reproducibility best and worst ratios were 95.0% and 98.3%, respectively. For GNB, 12%, 2.5% and 1.2% of MIC variations were within ±1, 2 or >2 two-fold dilutions of the mode value, respectively. For GPC, 17.5%, 4.1% and 2.5% of MIC variations were in a range of ±1, 2 and >2 two-fold dilutions, respectively, in comparison to the mode values.
4. Discussion
4.1. Main Findings
Compared to the BD Phoenix M50 AST and MIC gradient strips, the overall QMAC-dRAST CA for Enterobacterales, non-fermentative GNB, staphylococci and enterococci were 95.1%, 91.2%, 93.4% and 94.5%, respectively. The VME percentage was below 4% for all the groups except for staphylococci, which showed a VME rate of 7%. Compared to conventional AST, a significant decreased time to results was observed with a median of 6.7 h. Repeatability assays showed a high reliability of QMAC-dRAST AST results with best and worst ratios of 98.8% and 99.6%, respectively.
Most of the ME and VME observed with Staphylococcus species were due to oxacillin. The oxacillin MIC test and cefoxitin screen are essential for the detection of methicillin-resistant Staphylococcus strains. QMAC-dRAST AST includes both tests for S. aureus and S. lugdunensis, and for these species, all the methicillin-resistant strains were cefoxitin screen-positive despite oxacillin-susceptible MIC values. For coagulase-negative Staphylococcus (ConS), all the methicillin-resistant strains were associated with oxacillin-resistant MIC values, but 50% of ME was obtained for methicillin-susceptible ConS demonstrating an excellent sensitivity but a low specificity of methicillin-resistant ConS detection. Levofloxacin showed high rates of ME or VME with Staphylococcus spp., Enterococcus spp. and non-fermentative GNB. Therefore, a systematic verification of levofloxacin by another method would be required before reporting the final results. A previous study evaluating the former version of the QMAC-dRAST with GPC bacteria reported ME and VME with glycopeptides that we did not observe in comparison to the BD Phoenix M50 [22]. Importantly, no discrepancies were observed for glycopeptide resistance with VRE in our study.
For Enterobacterales, most of the ME and VME were obtained with β-lactams. For non-fermentative GNB, VME were obtained for levofloxacin and ME with cefepime, piperacillin–tazobactam and trimethoprim–sulfamethoxazole. Similar performances were reported by Grohs et al. with the former version of the QMAC-dRAST for Enterobacterales, but they observed more ME with non-fermentative bacteria and β-lactams [23]. ESBL producers were correctly detected by the QMAC-dRAST. As observed in this study, ESBL screening interference was observed and expected with K1 and SHV-1 producing strains as these enzymes are associated with a resistance to third generation cephalosporins. The QMAC-dRAST prototype used in this study was not equipped with an expert system for the detection of carbapenemase-producing strains. However, 10 out of the 12 carbapenemase-positive strains would have been detected by using the EUCAST meropenem screening cut-off of 0.125 mg/L for carbapenemase-producing Enterobacterales. The two meropenem MIC values inferior to 0.12 were obtained with OXA-48, a carbapenemase known for its weak hydrolytic activity [24,25,26].
Finally, repeatability experiments showed minor variations in MIC results, while reproducibility assays provided more dispersed MIC values, particularly with Pseudomonas aeruginosa and Staphylococcus spp.
4.2. Limitation
Among the 250 ASTs performed with the QMAC-dRAST, 194 were performed from blood cultures spiked with well-characterized clinical isolates to increase the diversity of bacterial species and resistance phenotypes. Spiking of blood culture was standardized for the inoculum, incubation time and time delay processing of the sample upon blood culture positivity. Another extensive study should be conducted to provide a more precise performance of the QMAC-dRAST in the routine using patients’ positive blood culture so as to cover the diversity of pre-analytical and analytical parameters (clinical isolates, antimicrobial resistance phenotypes, infectious origin of the bacteremia, drug treatment, blood culture incubation time, time delay of positive blood culture processing) that may influence the performance of the QMAC-dRAST. In addition, the isolates tested in this study were characterized by a low prevalence of antibiotic resistance that may introduce a bias in the rate of ME and VME results.
4.3. Implication
The QMAC-dRAST system delivered AST results with an overall median time of 6.7 h (range: 4.7–7.9) allowing a rapid turnaround time for antibiotic regimen guidance. Significant benefits to the patients and hospitals with rapid AST systems are expected but would need to be analyzed in clinical studies, especially because these tests are more expensive than conventional AST methods. In countries with a low prevalence of antimicrobial resistance, the need for rapid AST can be debated as the maintenance of initial empirical antimicrobial therapy followed by antibiotic de-escalation are the strategies most applied for patients with severe sepsis that do not absolutely require rapid AST [27,28,29]. Studies considering patient clinical outcomes, the prevalence of antimicrobial resistance, organization of hospital units, therapeutic strategies and the cost of AST methods would be of interest to evaluate the benefits from rapid AST in healthcare systems.
5. Conclusions
In conclusion, the QMAC-dRAST is an easy-to-use system providing reliable AST performance. High performances were obtained with Enterobacterales and some improvements could be required for GPC, especially with ConS and oxacillin.
Supplementary Materials
The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/microorganisms10061212/s1, Table S1: List of antibiotics tested for each bacterial group included in the study; Table S2: Distribution of amikacin MICs obtained with the QMAC-dRAST versus the reference methods for gram-negative bacteria; Table S3: Distribution of ampicillin MICs obtained with the QMAC-dRAST versus the reference methods for gram-negative bacteria; Table S4: Distribution of amoxicillin-clavulanate MICs obtained with the QMAC-dRAST versus the reference methods for gram-negative bacteria; Table S5: Distribution of cefepime MICs obtained with the QMAC-dRAST versus the reference methods for gram-negative bacteria; Table S6: Distribution of ceftazidime MICs obtained with the QMAC-dRAST versus the reference methods for gram-negative bacteria; Table S7: Distribution of ceftazidime-avibactam MICs obtained with the QMAC-dRAST versus the reference methods for gram-negative bacteria; Table S8: Distribution of ciprofloxacin MICs obtained with the QMAC-dRAST versus the reference methods for gram-negative bacteria; Table S9: Distribution of gentamicin MICs obtained with the QMAC-dRAST versus the reference methods for gram-negative bacteria; Table S10: Distribution of imipenem MICs obtained with the QMAC-dRAST versus the reference methods for gram-negative bacteria; Table S11: Distribution of levofloxacin MICs obtained with the QMAC-dRAST versus the reference methods for gram-negative bacteria; Table S12: Distribution of meropenem MICs obtained with the QMAC-dRAST versus the reference methods for gram-negative bacteria; Table S13: Distribution of piperacillin-tazobactam MICs obtained with the QMAC-dRAST versus the reference methods for gram-negative bacteria; Table S14: Distribution of ampicillin MICs obtained with the QMAC-dRAST versus the reference methods for gram-positive bacteria; Table S15: Distribution of clindamycin MICs obtained with the QMAC-dRAST versus the reference methods for gram-positive bacteria; Table S16: Distribution of daptomycin MICs obtained with the QMAC-dRAST versus the reference methods for gram-positive bacteria; Table S17: Distribution of gentamicin MICs obtained with the QMAC-dRAST versus the reference methods for gram-positive bacteria; Table S18: Distribution of gentamicin-high MICs obtained with the QMAC-dRAST versus the reference methods for gram-positive bacteria; Table S19: Distribution of levofloxacin MICs obtained with the QMAC-dRAST versus the reference methods for gram-positive bacteria; Table S20: Distribution of linezolid MICs obtained with the QMAC-dRAST versus the reference methods for gram-positive bacteria; Table S21: Distribution of oxacillin MICs obtained with the QMAC-dRAST versus the reference methods for gram-positive bacteria; Table S22: Distribution of penicillin G MICs obtained with the QMAC-dRAST versus the reference methods for gram-positive bacteria; Table S23: Distribution of teicoplanin MICs obtained with the QMAC-dRAST versus the reference methods for gram-positive bacteria; Table S24: Distribution of tetracyclin MICs obtained with the QMAC-dRAST versus the reference methods for gram-positive bacteria; Table S25: Distribution of vancomycin MICs obtained with the QMAC-dRAST versus the reference methods for gram-positive bacteria; Table S26: Analysis of QMAC-dRast results for each bacterial species.
Author Contributions
Conceptualization, A.C.; methodology, A.C., G.P. and M.R.; software, A.C., G.P. and M.R.; validation, A.C., G.P. and M.R.; formal analysis, A.C., G.P. and M.R.; investigation, A.C., G.P. and M.R.; resources, A.C.; data curation, A.C., G.P. and M.R; writing—original draft preparation, A.C. and M.R.; writing—review and editing, A.C., G.P., G.G. and M.R.; visualization, A.C., G.P. and M.R.; supervision, A.C.; project administration, A.C.; funding acquisition, A.C. All authors have read and agreed to the published version of the manuscript.
Funding
Quantamatrix supported this study by providing the QMAC-dRAST prototype as well as consumables and reagents.
Institutional Review Board Statement
This study was evaluated by our Ethics Committee (CER-VD) according to national law (Swiss Federal Act on Human Research) and they judged that it did not deserve a specific approval being only a quality assessment of diagnostic tests.
Informed Consent Statement
Not applicable.
Data Availability Statement
Data supporting reported results will be available upon request for the peer-review process.
Acknowledgments
We warmly thank Albert Soler Girones, Nathan Schlechten and Shklqim Gizha for their wonderful support in this project.
Conflicts of Interest
The authors declare no conflict of interest.
Abbreviations
AST: antibiotic susceptibility testing, GPC: Gram-positive cocci, GNB: Gram-negative bacilli, CA: categorical agreement, VME: very major error, me: minor error, ME: major error, MIC: minimum inhibitory concentration, ESBL: extended spectrum β-lactamase, ConS: coagulase-negative Staphylococcus, S: susceptible, I: susceptible at increased exposure, R: resistant.
References
- Goto, M.; Al-Hasan, M.N. Overall burden of bloodstream infection and nosocomial bloodstream infection in North America and Europe. Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis. 2013, 19, 501–509. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Anderson, D.J.; Moehring, R.W.; Sloane, R.; Schmader, K.E.; Weber, D.J.; Fowler, V.G., Jr.; Smathers, E.; Sexton, D.J. Bloodstream infections in community hospitals in the 21st century: A multicenter cohort study. PLoS ONE 2014, 9, e91713. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lambregts, M.M.C.; Wijnakker, R.; Bernards, A.T.; Visser, L.G.; Cessie, S.L.; Boer, M.G.J. Mortality after Delay of Adequate Empiric Antimicrobial Treatment of Bloodstream Infection. J. Clin. Med. 2020, 9, 1378. [Google Scholar] [CrossRef]
- Paoli, C.J.; Reynolds, M.A.; Sinha, M.; Gitlin, M.; Crouser, E. Epidemiology and Costs of Sepsis in the United States-An Analysis Based on Timing of Diagnosis and Severity Level. Crit. Care Med. 2018, 46, 1889–1897. [Google Scholar] [CrossRef] [PubMed]
- Meda, M.; Clayton, J.; Varghese, R.; Rangaiah, J.; Grundy, C.; Dashti, F.; Garner, D.; Groves, K.; Fitzmaurice, K.; Hutley, E. What are the critical steps in processing blood cultures? A prospective audit evaluating current practice of reporting blood cultures in a centralised laboratory serving secondary care hospitals. J. Clin. Pathol. 2017, 70, 361–366. [Google Scholar] [CrossRef] [PubMed]
- Tabak, Y.P.; Vankeepuram, L.; Ye, G.; Jeffers, K.; Gupta, V.; Murray, P.R. Blood Culture Turnaround Time in U.S. Acute Care Hospitals and Implications for Laboratory Process Optimization. J. Clin. Microbiol. 2018, 56, e00500-18. [Google Scholar] [CrossRef] [Green Version]
- Edmiston, C.E.; Garcia, R.; Barnden, M.; DeBaun, B.; Johnson, H.B. Rapid diagnostics for bloodstream infections: A primer for infection preventionists. Am. J. Infect. Control 2018, 46, 1060–1068. [Google Scholar] [CrossRef] [Green Version]
- Prod’hom, G.; Durussel, C.; Greub, G. A simple blood-culture bacterial pellet preparation for faster accurate direct bacterial identification and antibiotic susceptibility testing with the VITEK 2 system. J. Med. Microbiol. 2013, 62, 773–777. [Google Scholar] [CrossRef] [Green Version]
- Choi, J.; Yoo, J.; Lee, M.; Kim, E.G.; Lee, J.S.; Lee, S.; Joo, S.; Song, S.H.; Kim, E.C.; Lee, J.C.; et al. A rapid antimicrobial susceptibility test based on single-cell morphological analysis. Sci. Transl. Med. 2014, 6, 267ra174. [Google Scholar] [CrossRef]
- Longo, G.; Alonso-Sarduy, L.; Rio, L.M.; Bizzini, A.; Trampuz, A.; Notz, J.; Dietler, G.; Kasas, S. Rapid detection of bacterial resistance to antibiotics using AFM cantilevers as nanomechanical sensors. Nat. Nanotechnol. 2013, 8, 522–526. [Google Scholar] [CrossRef]
- Choi, J.; Jeong, H.Y.; Lee, G.Y.; Han, S.; Han, S.; Jin, B.; Lim, T.; Kim, S.; Kim, D.Y.; Kim, H.C.; et al. Direct, rapid antimicrobial susceptibility test from positive blood cultures based on microscopic imaging analysis. Sci. Rep. 2017, 7, 1148. [Google Scholar] [CrossRef] [PubMed]
- Hong, J.S.; Kim, D.; Kang, D.Y.; Park, B.Y.; Yang, S.; Yoon, E.J.; Lee, H.; Jeong, S.H. Evaluation of the BD Phoenix M50 Automated Microbiology System for Antimicrobial Susceptibility Testing with Clinical Isolates in Korea. Microb. Drug Resist. 2019, 25, 1142–1148. [Google Scholar] [CrossRef] [PubMed]
- Junkins, A.D.; Lockhart, S.R.; Heilmann, K.P.; Dohrn, C.L.; Von Stein, D.L.; Winokur, P.L.; Doern, G.V.; Richter, S.S. BD Phoenix and Vitek 2 detection of mecA-mediated resistance in Staphylococcus aureus with cefoxitin. J. Clin. Microbiol. 2009, 47, 2879–2882. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Snyder, J.W.; Munier, G.K.; Johnson, C.L. Direct comparison of the BD phoenix system with the MicroScan WalkAway system for identification and antimicrobial susceptibility testing of Enterobacteriaceae and nonfermentative gram-negative organisms. J. Clin. Microbiol. 2008, 46, 2327–2333. [Google Scholar] [CrossRef] [Green Version]
- Croxatto, A.; Coste, A.T.; Pillonel, T.; Bertelli, C.; Greub, G.; Prod’hom, G. Evaluation of the BD Phoenix CPO Detect Test for the detection of carbapenemase producers. Clin. Microbiol. Infect. 2020, 26, 644.e9–644.e15. [Google Scholar] [CrossRef] [Green Version]
- Jacot, D.; Sarton-Loheac, G.; Coste, A.T.; Bertelli, C.; Greub, G.; Prod’hom, G.; Croxatto, A. Performance evaluation of the Becton Dickinson Kiestra IdentifA/SusceptA. Clin. Microbiol. Infect. 2021, 27, 1167.e9–1167.e17. [Google Scholar] [CrossRef]
- Yonezawa, T.; Watari, T.; Ashizawa, K.; Hanada, D.; Yanagiya, T.; Watanabe, N.; Terada, T.; Tomoda, Y.; Fujii, S. Development of an improved rapid BACpro® protocol and a method for direct identification from blood-culture-positive bottles using matrix-assisted laser desorption ionization time-of-flight mass spectrometry. J. Microbiol. Methods 2018, 148, 138–144. [Google Scholar] [CrossRef]
- Hanaki, H.; Kubo, R.; Nakano, T.; Kurihara, M.; Sunagawa, K. Characterization of HMRZ-86: A novel chromogenic cephalosporin for the detection of extended-spectrum beta-lactamases. J. Antimicrob. Chemother. 2004, 53, 888–889. [Google Scholar] [CrossRef]
- Tijet, N.; Boyd, D.; Patel, S.N.; Mulvey, M.R.; Melano, R.G. Evaluation of the Carba NP test for rapid detection of carbapenemase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2013, 57, 4578–4580. [Google Scholar] [CrossRef] [Green Version]
- FDA. Guidance for Industry and FDA. Class II Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems; US Department of Health and Human Services: Silver Spring, MD, USA, 2009. [Google Scholar]
- Woods, C.R. Macrolide-inducible resistance to clindamycin and the D-test. Pediatric Infect. Dis. J. 2009, 28, 1115–1118. [Google Scholar] [CrossRef] [Green Version]
- Huh, H.J.; Song, D.J.; Shim, H.J.; Kwon, W.K.; Park, M.S.; Ryu, M.R.; Cho, E.H.; Oh, J.; Yoo, I.Y.; Lee, N.Y. Performance evaluation of the QMAC-dRAST for staphylococci and enterococci isolated from blood culture: A comparative study of performance with the VITEK-2 system. J. Antimicrob. Chemother. 2018, 73, 1267–1271. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Grohs, P.; Rondinaud, E.; Fourar, M.; Rouis, K.; Mainardi, J.L.; Podglajen, I. Comparative evaluation of the QMAC-dRAST V2.0 system for rapid antibiotic susceptibility testing of Gram-negative blood culture isolates. J. Microbiol. Methods 2020, 172, 105902. [Google Scholar] [CrossRef] [PubMed]
- Fattouh, R.; Tijet, N.; McGeer, A.; Poutanen, S.M.; Melano, R.G.; Patel, S.N. What Is the Appropriate Meropenem MIC for Screening of Carbapenemase-Producing Enterobacteriaceae in Low-Prevalence Settings? Antimicrob. Agents Chemother. 2015, 60, 1556–1559. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Oueslati, S.; Nordmann, P.; Poirel, L. Heterogeneous hydrolytic features for OXA-48-like β-lactamases. J. Antimicrob. Chemother. 2015, 70, 1059–1063. [Google Scholar] [CrossRef] [Green Version]
- Poirel, L.; Potron, A.; Nordmann, P. OXA-48-like carbapenemases: The phantom menace. J. Antimicrob. Chemother. 2012, 67, 1597–1606. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Garnacho-Montero, J.; Gutiérrez-Pizarraya, A.; Escoresca-Ortega, A.; Corcia-Palomo, Y.; Fernández-Delgado, E.; Herrera-Melero, I.; Ortiz-Leyba, C.; Márquez-Vácaro, J.A. De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med. 2014, 40, 32–40. [Google Scholar] [CrossRef]
- Heenen, S.; Jacobs, F.; Vincent, J.-L. Antibiotic strategies in severe nosocomial sepsis: Why do we not de-escalate more often? Crit. Care Med. 2012, 40, 1404–1409. [Google Scholar] [CrossRef]
- Morel, J.; Casoetto, J.; Jospé, R.; Aubert, G.; Terrana, R.; Dumont, A.; Molliex, S.; Auboyer, C. De-escalation as part of a global strategy of empiric antibiotherapy management. A retrospective study in a medico-surgical intensive care unit. Crit. Care 2010, 14, R225. [Google Scholar] [CrossRef] [Green Version]
Figure 1.
Median time to results for bacterial groups and antimicrobial agents. The box extends from the 25th to 75th percentiles and the whiskers from the smallest to the largest values. (A) Median time to results for the different bacterial classes. Median time to results per antibiotic for (B) Enterobacterales, (C) non-fermentative GNB, (D) Staphylococcus spp. and (E) Enterococcus spp. AK: amikacin, AMC: amoxicillin–clavulanate, AMP: ampicillin, CAZ: ceftazidime, CIP: ciprofloxacin, CM: clindamycin, CTX: cefotaxime, CZA: ceftazidime–avibactam, DAP: daptomycin, Ery: erythromycin, FEP: cefepime, FU: fusidic acid, GM: gentamicin, IMI: imipenem, LEV: levofloxacin, LZ: linezolid, MEM: meropenem, OXA: oxacillin, PG: penicillin G, PIP: piperacillin, RIF: rifampicin, TE: teicoplanin, TZP: piperacillin–tazobactam, SXT: trimethoprim–sulfamethoxazole, VA: vancomycin.
Figure 1.
Median time to results for bacterial groups and antimicrobial agents. The box extends from the 25th to 75th percentiles and the whiskers from the smallest to the largest values. (A) Median time to results for the different bacterial classes. Median time to results per antibiotic for (B) Enterobacterales, (C) non-fermentative GNB, (D) Staphylococcus spp. and (E) Enterococcus spp. AK: amikacin, AMC: amoxicillin–clavulanate, AMP: ampicillin, CAZ: ceftazidime, CIP: ciprofloxacin, CM: clindamycin, CTX: cefotaxime, CZA: ceftazidime–avibactam, DAP: daptomycin, Ery: erythromycin, FEP: cefepime, FU: fusidic acid, GM: gentamicin, IMI: imipenem, LEV: levofloxacin, LZ: linezolid, MEM: meropenem, OXA: oxacillin, PG: penicillin G, PIP: piperacillin, RIF: rifampicin, TE: teicoplanin, TZP: piperacillin–tazobactam, SXT: trimethoprim–sulfamethoxazole, VA: vancomycin.
Table 1.
Distribution of bacterial species tested in the study and their associated antibiotic resistance mechanisms (n = 250).
Table 1.
Distribution of bacterial species tested in the study and their associated antibiotic resistance mechanisms (n = 250).
| Bacterial Species | N° Bacteria | Resistance Mechanisms | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Spiking | |||||||||||||
| No | Yes | ||||||||||||
| All | 56 | 194 | Wild Type | AmpC | ESBL | AmpC ESBL | AmpC Carbapenemase | Probable K1 | Probable SHV-1 | Carbapenemase | VRE | Methicillin-R | Total |
| Enterobacterales, total | 28 | 102 | 130 | ||||||||||
| Escherichia coli | 16 | 15 | 17 | 2 | 12 | 31 | |||||||
| Klebsiella pneumoniae | 5 | 16 | 8 | 6 | 3 | 4 | 21 | ||||||
| Enterobacter cloacae | 0 | 14 | 7 | 4 | 3 | 14 | |||||||
| Proteus mirabilis | 2 | 9 | 10 | 1 | 11 | ||||||||
| Klebsiella aerogenes | 1 | 9 | 10 | 10 | |||||||||
| Klebsiella oxytoca | 1 | 9 | 5 | 2 | 3 | 10 | |||||||
| Serratia marcescens | 0 | 10 | 10 | 10 | |||||||||
| Proteus vulgaris | 0 | 6 | 6 | 6 | |||||||||
| Proteus hauseri | 0 | 5 | 5 | 5 | |||||||||
| Citrobacter freundii | 1 | 3 | 3 | 1 | 4 | ||||||||
| Morganella morganii | 1 | 3 | 4 | 4 | |||||||||
| Citrobacter koseri | 0 | 3 | 3 | 3 | |||||||||
| Salmonella spp. | 1 | 0 | 1 | 1 | |||||||||
| Non-fermentative GNB, total | 5 | 15 | 20 | ||||||||||
| Pseudomonas aeruginosa | 4 | 9 | 11 | 2 | 13 | ||||||||
| Acinetobacter baumannii | 0 | 5 | 3 | 2 | 5 | ||||||||
| Acinetobacter spp. | 1 | 0 | 1 | 1 | |||||||||
| Stenotrophomonas maltophilia | 0 | 1 | 1 | 1 | |||||||||
| Staphylococcus spp., total | 20 | 49 | 69 | ||||||||||
| Staphylococcus aureus | 9 | 15 | 9 | 15 | 24 | ||||||||
| Staphylococcus epidermidis | 8 | 11 | 10 | 9 | 19 | ||||||||
| Staphylococcus hominis | 2 | 7 | 7 | 2 | 9 | ||||||||
| Staphylococcus capitis | 1 | 6 | 6 | 1 | 7 | ||||||||
| Staphylococcus haemolyticus | 0 | 5 | 4 | 1 | 5 | ||||||||
| Staphylococcus lugdunensis | 0 | 5 | 4 | 1 | 5 | ||||||||
| Enterococcus spp., total | 3 | 28 | 31 | ||||||||||
| Enterococcus faecium | 0 | 14 | 8 | 6 | 14 | ||||||||
| Enterococcus faecalis | 3 | 10 | 12 | 1 | 13 | ||||||||
| Enterococcus casseliflavus | 0 | 3 | 3 | 3 | |||||||||
| Enterococcus gallinarum | 0 | 1 | 1 | 1 | |||||||||
| Total | 125 | 42 | 20 | 5 | 4 | 3 | 3 | 8 | 11 | 29 | 250 | ||
N°: number, ESBL: extended spectrum beta-Lactamase, GNB: Gram-negative bacilli, K1: Klebsiella oxytoca isolates hyperproducing K1 β-lactamase, SHV-1: Klebsiella pneumoniae isolates hyperproducing SHV-1 β-lactamase, VRE: vancomycin-resistant Enterococcus.
Table 2.
Performance characteristics of the QMAC-dRAST by antibiotic and bacterial group.
| N° of Antibiotics Tested | CA | CA% | me | me% | ME | ME%S | VME | VME%R | S | S_% | R | R_% | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Enterobacterales | |||||||||||||
| Amikacin | 130 | 130 | 100 | 130 | 100 | 0 | 0.0 | ||||||
| Amoxicillin–Clavulanate | 130 | 125 | 96.2 | 3 | 5.9 | 2 | 2.5 | 51 | 39.2 | 79 | 60.8 | ||
| Ampicillin | 130 | 130 | 100 | 16 | 12.3 | 114 | 87.7 | ||||||
| Ceftazidime | 130 | 114 | 87.7 | 11 | 8.5 | 5 | 5.1 | 98 | 75.4 | 32 | 24.6 | ||
| Ceftazidime–Avibactam | 129 | 129 | 100 | 129 | 100 | 0 | 0.0 | ||||||
| Ciprofloxacin | 129 | 123 | 95.3 | 5 | 3.9 | 1 | 1 | 104 | 80.6 | 25 | 19.4 | ||
| Cefepime | 130 | 116 | 89.2 | 9 | 6.9 | 5 | 4.6 | 108 | 83.1 | 22 | 16.9 | ||
| Gentamicin | 130 | 125 | 96.2 | 4 | 3.1 | 1 | 5.6 | 112 | 86.2 | 18 | 13.8 | ||
| Imipenem | 118 | 103 | 87.3 | 15 | 12.7 | 115 | 97.5 | 3 | 2.5 | ||||
| Levofloxacin | 130 | 120 | 92.3 | 10 | 7.7 | 114 | 87.7 | 16 | 12.3 | ||||
| Meropenem | 130 | 129 | 99.2 | 1 | 0.8 | 129 | 99.2 | 1 | 0.8 | ||||
| Piperacillin–Tazobactam | 130 | 122 | 93.8 | 6 | 4.6 | 1 | 1 | 1 | 3.4 | 101 | 77.7 | 29 | 22.3 |
| Trimethoprim–Sulfamethoxazole | 130 | 128 | 98.5 | 1 | 0.8 | 1 | 1.1 | 89 | 68.5 | 41 | 31.5 | ||
| Non-fermentative GNB | |||||||||||||
| Amikacin | 19 | 18 | 94.7 | 1 | 5.3 | 16 | 84.2 | 3 | 15.8 | ||||
| Ceftazidime | 13 | 13 | 100 | 8 | 61.5 | 5 | 38.5 | ||||||
| Ceftazidime–Avibactam | 12 | 12 | 100 | 9 | 75 | 3 | 25.0 | ||||||
| Ciprofloxacin | 19 | 17 | 89.5 | 2 | 10.5 | 14 | 73.7 | 5 | 26.3 | ||||
| Cefepime | 13 | 11 | 84.6 | 2 | 22.2 | 9 | 69.2 | 4 | 30.8 | ||||
| Gentamicin | 18 | 18 | 100 | 12 | 66.7 | 6 | 33.3 | ||||||
| Imipenem | 19 | 18 | 94.7 | 1 | 5.3 | 12 | 63.2 | 7 | 36.8 | ||||
| Levofloxacin | 19 | 17 | 89.5 | 2 | 25 | 11 | 57.9 | 8 | 42.1 | ||||
| Meropenem | 19 | 17 | 89.5 | 2 | 10.5 | 14 | 73.7 | 5 | 26.3 | ||||
| Piperacillin–Tazobactam | 13 | 11 | 84.6 | 2 | 20 | 10 | 76.9 | 3 | 23.1 | ||||
| Trimethoprim–Sulfamethoxazole | 7 | 4 | 57.1 | 2 | 28.6 | 1 | 16.7 | 6 | 85.7 | 1 | 14.3 | ||
| Staphylococcus spp. | |||||||||||||
| Clindamycin | 69 | 67 | 97.1 | 1 | 1.4 | 1 | 1.8 | 58 | 84.1 | 11 | 15.9 | ||
| Daptomycin | 69 | 68 | 98.6 | 1 | 1.4 | 69 | 100 | 0 | 0.0 | ||||
| Gentamicin | 69 | 67 | 97.1 | 1 | 2 | 1 | 5.6 | 51 | 73.9 | 18 | 26.1 | ||
| Linezolid | 69 | 69 | 100 | 69 | 100 | 0 | 0.0 | ||||||
| Levofloxacin | 69 | 60 | 87 | 1 | 1.4 | 8 | 17 | 48 | 69.6 | 21 | 30.4 | ||
| Oxacillin | 69 | 46 | 66.7 | 16 | 50 | 7 | 18.9 | 32 | 46.4 | 37 | 53.6 | ||
| Penicillin G | 24 | 24 | 100 | 1 | 4.2 | 23 | 95.8 | ||||||
| Teicoplanin | 69 | 68 | 98.6 | 1 | 1.5 | 65 | 94.2 | 4 | 5.8 | ||||
| Vancomycin | 69 | 69 | 100 | 69 | 100 | 0 | 0.0 | ||||||
| Enterococcus spp. | |||||||||||||
| Ampicillin | 31 | 26 | 83.9 | 3 | 9.7 | 2 | 8 | 25 | 80.6 | 6 | 19.4 | ||
| Gentamicin-Syn | 31 | 30 | 96.8 | 1 | 3.7 | 27 | 87.1 | 4 | 12.9 | ||||
| Linezolid | 31 | 30 | 96.8 | 1 | 100 | 30 | 96.8 | 1 | 3.2 | ||||
| Levofloxacin | 26 | 24 | 92.3 | 2 | 11.1 | 18 | 69.2 | 8 | 30.8 | ||||
| Teicoplanin | 31 | 31 | 100 | 24 | 77.4 | 7 | 22.6 | ||||||
| Vancomycin | 31 | 30 | 96.8 | 1 | 4.8 | 21 | 67.7 | 10 | 32.3 | ||||
| Total | 2604 | 2459 | 94.4 | 74 | 2.8 | 56 | 2.8 | 15 | 2.6 | 2025 | 77.77 | 579 | 22.2 |
GNB: Gram-negative bacteria, N°: number, me: minor error, ME: major error, ME%S: ME rate (percentage of major error divided by the number of susceptible strains), VME: very major error, VME%R: VME rate (percentage of very major error divided by the number of resistant strains), S: susceptible, R: resistant, S_%: percentage of antibiotics that exhibit cmi values interpreted as S or I. R_%: percentage of antibiotics that exhibit cmi values interpreted as R.
Table 3.
Repeatability results obtained with the QMAC-dRAST.
| QMAC-dRAST MICs that Differed from the Mode Value by the Indicated Dilution | ||||||||
|---|---|---|---|---|---|---|---|---|
| <−2 | −2 | −1 | 0 | 1 | 2 | >2 | ||
| Enterobacterales | n | 0 | 0 | 11 | 454 | 15 | 0 | 0 |
| % | 0 | 0 | 3.56 | 92.40 | 2.88 | 0.48 | 0 | |
| Pseudomonas aeruginosa | n | 0 | 2 | 7 | 101 | 0 | 0 | 0 |
| % | 0 | 1.82 | 6.36 | 91.82 | 0 | 0 | 0 | |
| Staphylococcus spp. | n | 0 | 1 | 14 | 336 | 10 | 5 | 4 |
| % | 0 | 0.27 | 3.78 | 90.81 | 2.70 | 1.35 | 1.08 | |
| Enterococcus spp. | n | 0 | 0 | 5 | 60 | 5 | 0 | 0 |
| % | 0 | 0 | 7.14 | 85.71 | 7.14 | 0 | 0 | |
| Total | n | 0 | 3 | 37 | 961 | 30 | 5 | 4 |
| % | 0 | 0.29 | 3.56 | 92.40 | 2.88 | 0.48 | 0.38 | |
Table 4.
Reproducibility results obtained with the QMAC-dRAST.
| QM-dRAST MICs that Differed from the Mode Value by the Indicated Dilution | ||||||||
|---|---|---|---|---|---|---|---|---|
| <−2 | −2 | −1 | 0 | 1 | 2 | >2 | ||
| Enterobacterales | n | 0 | 4 | 21 | 424 | 25 | 1 | 5 |
| % | 0 | 0.83 | 4.38 | 88.33 | 5.21 | 0.21 | 1.04 | |
| P. aeruginosa | n | 0 | 6 | 12 | 71 | 15 | 4 | 2 |
| % | 0 | 5.45 | 10.91 | 64.55 | 13.64 | 3.64 | 1.82 | |
| Staphylococcus spp. | n | 0 | 10 | 40 | 277 | 27 | 5 | 11 |
| % | 0 | 2.70 | 10.81 | 74.86 | 7.30 | 1.35 | 2.97 | |
| Enterococcus spp. | n | 0 | 3 | 6 | 57 | 4 | 0 | 0 |
| % | 0 | 4.29 | 8.57 | 81.43 | 5.71 | 0 | 0 | |
| Total | n | 0 | 23 | 79 | 829 | 71 | 10 | 18 |
| % | 0 | 2.23 | 7.67 | 80.49 | 6.89 | 0.97 | 1.75 | |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Rosselin, M.; Prod’hom, G.; Greub, G.; Croxatto, A. Performance Evaluation of the Quantamatrix QMAC-dRAST System for Rapid Antibiotic Susceptibility Testing Directly from Blood Cultures. Microorganisms 2022, 10, 1212. https://doi.org/10.3390/microorganisms10061212
AMA Style
Rosselin M, Prod’hom G, Greub G, Croxatto A. Performance Evaluation of the Quantamatrix QMAC-dRAST System for Rapid Antibiotic Susceptibility Testing Directly from Blood Cultures. Microorganisms. 2022; 10(6):1212. https://doi.org/10.3390/microorganisms10061212
Chicago/Turabian StyleRosselin, Manon, Guy Prod’hom, Gilbert Greub, and Antony Croxatto. 2022. "Performance Evaluation of the Quantamatrix QMAC-dRAST System for Rapid Antibiotic Susceptibility Testing Directly from Blood Cultures" Microorganisms 10, no. 6: 1212. https://doi.org/10.3390/microorganisms10061212
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
